These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22710337)

  • 1. Radiotherapy: radioiodine in thyroid cancer-how to minimize side effects.
    Reiners C; Luster M
    Nat Rev Clin Oncol; 2012 Jun; 9(8):432-4. PubMed ID: 22710337
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.
    Sgouros G
    J Nucl Med; 2005 May; 46(5):899-900; author reply 901. PubMed ID: 15872367
    [No Abstract]   [Full Text] [Related]  

  • 3. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
    Lassmann M; Luster M; Hänscheid H; Reiners C
    J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient release issue reopened.
    J Nucl Med; 2010 Dec; 51(12):13N. PubMed ID: 21098785
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
    Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
    Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.
    Lassmann M; Hänscheid H; Reiners C; Thomas SR
    J Nucl Med; 2005 May; 46(5):900-1; author reply 901. PubMed ID: 15872369
    [No Abstract]   [Full Text] [Related]  

  • 8. Professional groups respond.
    J Nucl Med; 2010 Dec; 51(12):13N. PubMed ID: 21098784
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory distress caused by radioiodine therapy in patients with differentiated thyroid cancer.
    Kinuya S; Yokoyama K; Michigishi T; Tonami N
    Ann Nucl Med; 2006 Aug; 20(7):499-502. PubMed ID: 17037283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer.
    Levy HA; Park CH
    Clin Nucl Med; 1987 Apr; 12(4):303-7. PubMed ID: 3581610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.
    Klein Hesselink EN; Brouwers AH; de Jong JR; van der Horst-Schrivers AN; Coppes RP; Lefrandt JD; Jager PL; Vissink A; Links TP
    J Nucl Med; 2016 Nov; 57(11):1685-1691. PubMed ID: 27339871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body scanning with radionuclides of iodine, and the controversy of "thyroid stunning".
    Kalinyak JE; McDougall IR
    Nucl Med Commun; 2004 Sep; 25(9):883-9. PubMed ID: 15319592
    [No Abstract]   [Full Text] [Related]  

  • 13. Thyroid blocking policy--revisited.
    Solanki KK; Bomanji JB; Waddington WA; Ell PJ;
    Nucl Med Commun; 2004 Nov; 25(11):1071-6. PubMed ID: 15577583
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved planning of radioiodine therapy for thyroid cancer.
    Medvedec M
    J Nucl Med; 2002 May; 43(5):714; author reply 714. PubMed ID: 11994536
    [No Abstract]   [Full Text] [Related]  

  • 15. Gonadal damage due to radioactive iodine (I131) treatment for thyroid carcinoma.
    Ahmed SR; Shalet SM
    Postgrad Med J; 1985 Apr; 61(714):361-2. PubMed ID: 4022871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer].
    Dietlein M; Dressler J; Farahati J; Leisner B; Moser E; Reiners C; Schicha H; Schober O
    Nuklearmedizin; 1999; 38(6A):221-2. PubMed ID: 10510812
    [No Abstract]   [Full Text] [Related]  

  • 17. Radioiodine in treatment of metastatic thyroid cancer.
    Dewan SS; Sharma SM; Ganatra RD
    Int J Nucl Med Biol; 1979; 6(4):213-4. PubMed ID: 528148
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ablative Radioiodtherapie bei niedrigem und intermediärem Rezidivrisiko. Höhere Überlebensrate beim Schilddrüsenkarzinom].
    Dietlein M; Drzezga A
    Nuklearmedizin; 2016 Jun; 55(3):71-6. PubMed ID: 27350003
    [No Abstract]   [Full Text] [Related]  

  • 19. [Is radioiodine ablation of residual thyroid tissue indicated after an operation for differentiated thyroid cancer?].
    Chebotareva ED; Shishkina VV
    Lik Sprava; 1997; (1):118-22. PubMed ID: 9221132
    [No Abstract]   [Full Text] [Related]  

  • 20. [The basis for radioiodine therapy in differentiated thyroid cancer].
    Haldemann AR
    Ther Umsch; 1999 Jul; 56(7):403-7. PubMed ID: 10434780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.